摘要
目的探讨丁苯酞序贯疗法联合双联抗血小板治疗脑梗死合并颈动脉粥样硬化(CAS)的短中期疗效,以及对患者血脂水平的影响。方法选取医院2020年1月至2022年12月收治的脑梗死合并CAS患者治疗140例,按随机数字表法分为观察组和对照组,各70例。对照组患者在常规治疗基础上联合双联抗血小板治疗,观察组患者在对照组治疗基础上联用丁苯酞序贯疗法,均治疗3个月。结果观察组治疗后1个月和3个月总有效率分别为92.86%和88.57%,均显著高于对照组的77.14%和68.57%(P<0.05)。治疗后3个月,观察组美国国立卫生研究院卒中量表(NIHSS)评分显著低于对照组(P<0.05),日常生活能力评定量表(ADL)评分显著高于对照组(P<0.05);观察组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均显著低于对照组(P<0.05),高密度脂蛋白胆固醇(HDL-C)水平显著高于对照组(P<0.05);观察组血清同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)和白细胞介素6(IL-6)水平均显著低于对照组(P<0.05)。观察组和对照组不良反应发生率相当(8.57%比7.14%,P=0.753)。结论丁苯酞序贯疗法联合双联抗血小板治疗脑梗死合并CAS的短中期疗效确切,可改善患者的神经功能和认知功能障碍,调控血脂,减轻炎性反应,且安全性高。
Objective To investigate the short to med-term efficacy of butylphthalide sequential therapy combined with dual antiplatelet therapy in the treatment of cerebral infarction with carotid atherosclerosis(CAS),and its effect on blood lipid levels of patients.Methods A total of 140 patients with CI combined with CAS admitted to the hospital from January 2020 to December 2022 were selected and divided into the observation group and the control group by the random number table method,with 70 cases in each group.The patients in the control group were treated with conventional therapy combined with dual antiplatelet therapy,on this basis,the patients in the observation group were treated with sequential therapy of butylphthalide.Both groups were treated for three months.Results The total effective rates in the observation group at one month and three months after treatment were 92.86%and 88.57%,which were significantly higher than 77.14%and 68.57%in the control group(P<0.05).After three months of treatment,the National Institutes of Health Stroke Scale(NIHSS)score in the observation group was significantly lower than that in the control group(P<0.05),and the Activity of Daily Living(ADL)score in the observation group was significantly higher than that in the control group(P<0.05).The levels of total cholesterol(TC),triacylglycerol(TG),and low-density lipoprotein cholesterol(LDL-C)in the observation group were significantly lower than those in the control group(P<0.05),while the high-density lipoprotein cholesterol(HDL-C)in the observation group was significantly higher than that in the control group(P<0.05).The levels of serum homocysteine(Hcy),high sensitivity C-reactive protein(hs-CRP),and interleukin-6(IL-6)in the observation group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was comparable to that in the control group(8.57%vs.7.14%,P=0.753).Conclusion Butylphthalide sequential therapy combined with dual antiplatelet therapy in the treatment of cerebral infarction complicated with CAS has short to mid-term efficacy and safety,which can improve cognitive dysfunction,regulate blood lipids,and reduce inflammatory reactions.
作者
杨娇
王琼芝
李秋云
YANG Jiao;WANG Qiongzhi;LI Qiuyun(Honghu People's Hospital,Jingzhou,Hubei,China 433200)
出处
《中国药业》
CAS
2023年第23期107-110,共4页
China Pharmaceuticals
基金
湖北省卫生健康委员会科研计划项目[wj2019m78]。
关键词
丁苯酞序贯疗法
双联抗血小板
脑梗死
颈动脉粥样硬化
短中期疗效
血脂
butylphthalide sequential therapy
dual antiplatelet therapy
cerebral infarction
carotid atherosclerosis
short to mid-term efficacy
blood lipids